Carlos Escande
Carlos Escande is a key member of Eolo Pharma, a Uruguayan startup focused on developing innovative treatments for obesity and type 2 diabetes. He is also a researcher at the renowned Institut Pasteur, where he contributes to scientific advancements in metabolic disorders. Recently, he was in the news for his role in the successful human trials of SANA, a groundbreaking drug that stimulates energy expenditure rather than suppressing appetite, marking a significant milestone for Uruguay's pharmaceutical contributions.
Not in the pool (under ¢1).
Recent news mentions
Carlos Escande, also a researcher at the Institut Pasteur in Montevideo, illustrated the effect of SANA in dialogue with Telemundo.
Cómo funciona el fármaco desarrollado por científicos uruguayos que promete efectos notables para combatir la obesidad
Uruguay· 2025-06-18
Carlos Escande, a member of Eolo Pharma and researcher at the Institut Pasteur, discussed the new therapeutic avenue for obesity and metabolic disorders.
Uruguay desarrolla su primer fármaco para combatir la obesidad y la diabetes tipo 2Uruguay· 2025-06-17